CEFPODOXIME PROXETIL

Post-LOE

cefpodoxime proxetil

PharmaIN

ANDAORALTABLET

Approved

Aug 2003

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

CEFPODOXIME PROXETIL (cefpodoxime proxetil) by PharmaIN is clinical pharmacology absorption and excretion: cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Approved for development of drug-resistant bacteria, maintain the effectiveness of cefpodoxime proxetil, other antibacterial drugs and 3 more indications. First approved in 2003.

Drug data last refreshed 22h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Absorption and Excretion: Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Following oral administration of 100 mg of cefpodoxime proxetil to fasting subjects, approximately 50% of the…

Worked on CEFPODOXIME PROXETIL at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

CEFPODOXIME PROXETIL

Mechanism of Action

Indications (6)